Abstract B10: Noninvasive pharmacodynamic markers of the dual mTORC1/2 inhibitor AZD2014 in combination with paclitaxel, in cisplatin-resistant ovarian carcinoma xenografts

Conclusions: A+P is effective in preclinical ovarian tumors, with additive growth inhibition and increased apoptosis. Very few metabolic changes were observed in P-treated tumors compared with V. The non-phospholipid changes in the metabolic profiles of A- and A+P-treated tumors are consistent with previous findings where similar metabolic profiles were found following mTOR inhibition (1). A+P treatment also caused decreases in PC (associated with reduced choline kinase expression) and other choline-related metabolites and these phospholipid changes may have potential as surrogate non-invasive markers for determining tumor response following AZD2014 and paclitaxel combination treatment.(1) Lin et al. Cell Symposia: Angiogenesis, Metabolic Regulation, and Cancer Biology in association with VIB, Belgium 2012.This work is supported by the CR-UK and EPSRC Cancer Imaging Centre in association with the MRC and Department of Health (England) grants C1060/A10334 and C1060/A16464, NHS funding to the NIHR Biomedical Research Centre. MOL is an NIHR Senior Investigator.Citation Format: Anne-Christine LF Wong Te-Fong, Efthymia Papaevangelou, Martin O. Leach, Udai Banerji, Yuen-Li Chung. Noninvasive pharmacodynamic markers of the dual mTORC1/2 inhibitor AZD2014 in combination with paclitaxel, in cisplatin-resistant ovarian carcinoma xenografts. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cance...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Signaling Pathways and Cancer Metabolism: Poster Presentations - Proffered Abstracts Source Type: research